These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16085057)

  • 41. Novel homozygous ALS2 nonsense mutation (p.Gln715X) in sibs with infantile-onset ascending spastic paralysis: the first cases from northwestern Europe.
    Verschuuren-Bemelmans CC; Winter P; Sival DA; Elting JW; Brouwer OF; Müller U
    Eur J Hum Genet; 2008 Nov; 16(11):1407-11. PubMed ID: 18523452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Solo/Trio8, a membrane-associated short isoform of Trio, modulates endosome dynamics and neurite elongation.
    Sun YJ; Nishikawa K; Yuda H; Wang YL; Osaka H; Fukazawa N; Naito A; Kudo Y; Wada K; Aoki S
    Mol Cell Biol; 2006 Sep; 26(18):6923-35. PubMed ID: 16943433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Loss of ERLIN2 function leads to juvenile primary lateral sclerosis.
    Al-Saif A; Bohlega S; Al-Mohanna F
    Ann Neurol; 2012 Oct; 72(4):510-6. PubMed ID: 23109145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytoskeletal defects in amyotrophic lateral sclerosis (motor neuron disease).
    Julien JP; Millecamps S; Kriz J
    Novartis Found Symp; 2005; 264():183-92; discussion 192-6, 227-30. PubMed ID: 15773754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chapter 15 Juvenile amyotrophic lateral sclerosis.
    Orban P; Devon RS; Hayden MR; Leavitt BR
    Handb Clin Neurol; 2007; 82():301-12. PubMed ID: 18808900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel mutation in the ALS2 gene in an iranian kurdish family with juvenile amyotrophic lateral sclerosis.
    Daneshmandpour Y; Bahmanpour Z; Kazeminasab S; Aghaei Moghadam E; Alehabib E; Chapi M; Tafakhori A; Aghaei N; Darvish H; Emamalizadeh B
    Amyotroph Lateral Scler Frontotemporal Degener; 2023 Feb; 24(1-2):148-151. PubMed ID: 35852402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GMAP-210 recruits gamma-tubulin complexes to cis-Golgi membranes and is required for Golgi ribbon formation.
    Ríos RM; Sanchís A; Tassin AM; Fedriani C; Bornens M
    Cell; 2004 Aug; 118(3):323-35. PubMed ID: 15294158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Personalized Treatment for Infantile Ascending Hereditary Spastic Paralysis Based on In Silico Strategies.
    Rossi Sebastiano M; Ermondi G; Sato K; Otomo A; Hadano S; Caron G
    Molecules; 2022 Oct; 27(20):. PubMed ID: 36296656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel centrosome and microtubules associated subcellular localization of Nogo-A: implications for neuronal development.
    Mi Y; Gao X; Ma Y; Gao J; Wang Z; Jin W
    Int J Biochem Cell Biol; 2014 Dec; 57():1-6. PubMed ID: 25286302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tetracycline-regulated gene expression in the NSC-34-tTA cell line for investigation of motor neuron diseases.
    Babetto E; Mangolini A; Rizzardini M; Lupi M; Conforti L; Rusmini P; Poletti A; Cantoni L
    Brain Res Mol Brain Res; 2005 Oct; 140(1-2):63-72. PubMed ID: 16125275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ALS2-related disorders in Spanish children.
    Nogueira E; Alarcón J; Garma C; Paredes C
    Neurol Sci; 2021 May; 42(5):2091-2094. PubMed ID: 33409823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protein 4.1R regulates interphase microtubule organization at the centrosome.
    Pérez-Ferreiro CM; Vernos I; Correas I
    J Cell Sci; 2004 Dec; 117(Pt 25):6197-206. PubMed ID: 15564380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AI-based protein structure databases have the potential to accelerate rare diseases research: AlphaFoldDB and the case of IAHSP/Alsin.
    Rossi Sebastiano M; Ermondi G; Hadano S; Caron G
    Drug Discov Today; 2022 Jun; 27(6):1652-1660. PubMed ID: 34958957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ALS pathogenesis: recent insights from genetics and mouse models.
    Swarup V; Julien JP
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):363-9. PubMed ID: 20728492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An interrupted beta-propeller and protein disorder: structural bioinformatics insights into the N-terminus of alsin.
    Soares DC; Barlow PN; Porteous DJ; Devon RS
    J Mol Model; 2009 Feb; 15(2):113-22. PubMed ID: 19023603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic background and gender effects on gross phenotypes in congenic lines of ALS2/alsin-deficient mice.
    Hadano S; Yoshii Y; Otomo A; Kunita R; Suzuki-Utsunomiya K; Pan L; Kakuta S; Iwasaki Y; Iwakura Y; Ikeda JE
    Neurosci Res; 2010 Oct; 68(2):131-6. PubMed ID: 20558214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ALS2-Related Motor Neuron Diseases: From Symptoms to Molecules.
    Miceli M; Exertier C; Cavaglià M; Gugole E; Boccardo M; Casaluci RR; Ceccarelli N; De Maio A; Vallone B; Deriu MA
    Biology (Basel); 2022 Jan; 11(1):. PubMed ID: 35053075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ALS2CL, the novel protein highly homologous to the carboxy-terminal half of ALS2, binds to Rab5 and modulates endosome dynamics.
    Hadano S; Otomo A; Suzuki-Utsunomiya K; Kunita R; Yanagisawa Y; Showguchi-Miyata J; Mizumura H; Ikeda JE
    FEBS Lett; 2004 Sep; 575(1-3):64-70. PubMed ID: 15388334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-ALS activity of alsin, the product of the ALS2 gene, and activity-dependent neurotrophic factor.
    Matsuoka M; Nishimoto I
    Neurodegener Dis; 2005; 2(3-4):135-8. PubMed ID: 16909018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Purification and functional analyses of ALS2 and its homologue.
    Hadano S; Ikeda JE
    Methods Enzymol; 2005; 403():310-21. PubMed ID: 16473597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.